23 May 2024 in The Turkish Journal of Pediatrics
Background. Acute respiratory failure is a prevalent condition in childhood with a high rate of mortality. Invasive mechanical ventilation support may be required for the management of these patients. Extracorporeal membrane oxygenation (ECMO) is a method used when ventilation support is insufficient. However, the less invasive extracorporeal carbon dioxide removal method can be used as an alternative in cases of hypercapnic respiratory failure. Case. A 9-year-old patient with cystic fibrosis presented to the hospital with acute respiratory failure due to pneumonia. Bilateral patchy areas of consolidation were evident in the chest x-ray. Invasive mechanical ventilation support was consequently provided to treat severe hypercapnia. Although peak and plateau pressure levels exceeded 32 cmH₂O (49 cmH₂O) and 28 cmH₂O (35 cmH₂O), respectively, the patient continued to have severe respiratory acidosis. Therefore extracorporeal carbon dioxide removal support was initiated to provide lung-protective ventilation. By Day 10, venovenous ECMO support was initiated due to deteriorating oxygenation. Conclusion. In cases where conventional invasive mechanical ventilation support is insufficient due to acute hypercapnic respiratory failure, extracorporeal carbon dioxide removal support, which is less invasive compared to ECMO, should be considered as an effective and reliable alternative method. However, it should be noted that extracorporeal carbon dioxide removal support does not affect oxygenation; it functions solely as a carbon dioxide removal system.
21 June 2025 in Transfusion and Apheresis Science
19 February 2026 in The Pediatric Infectious Disease Journal
Background: Human herpesvirus-6 (HHV-6) is a neurotropic virus that typically remains latent in immunocompetent individuals but may cause severe neurologic complications, including encephalitis, particularly in immunocompromised hosts. Rarely, HHV-6 encephalitis can also occur in immunocompetent children, often presenting with features of acute necrotizing encephalopathy. Cases: We report 2 cases of previously healthy toddlers who presented with fever, seizures and altered mental status. Neuroimaging revealed bilateral thalamic involvement consistent with acute necrotizing encephalopathy. HHV-6 DNA was detected in cerebrospinal fluid via polymerase chain reaction, confirming the diagnosis. Both patients received antiviral therapy with foscarnet, alongside immunomodulatory treatments including intravenous immunoglobulin, corticosteroids, plasmapheresis and, in 1 case, tocilizumab. Clinical outcomes varied, with 1 patient achieving full recovery and the other showing partial neurologic improvement. Conclusions: These cases highlight the potential for HHV-6 to cause severe encephalopathy in immunocompetent children. Early recognition, neuroimaging, and cerebrospinal fluid polymerase chain reaction testing are essential for diagnosis. Combined antiviral and immunomodulatory therapies may improve outcomes by addressing both viral replication and neuroinflammation.
1 August 2024 in Turkish Archives of Pediatrics
Cite this article as: Eyduran E, Cücan H, Havan M, Uçar T, Akar AR, Kendirli T. Use of intravesical tranexamic acid for severe macroscopic hematuria in a biventricular assist device-implanted child. Turk Arch Pediatr. 2024;59(5):508-509.
27 March 2026 in European Journal of Pediatrics
Carbapenem-resistant multidrug-resistant (MDR) and pandrug-resistant (PDR) Gram-negative infections represent a critical therapeutic challenge in pediatric intensive care units (PICUs), where effective treatment options are extremely limited. This study aimed to describe the real-world clinical outcomes and safety of ceftazidime–avibactam (CZA) in critically ill children with MDR/PDR infections. We conducted a retrospective observational study of pediatric patients aged 1 month to 18 years who received CZA for microbiologically confirmed MDR or PDR Gram-negative infections in a tertiary PICU between February 2021 and January 2025. Twenty-one critically ill children (median age 55 months, IQR 11–126) were included; two-thirds had underlying chronic conditions and 23.8% were immunosuppressed. Klebsiella pneumoniae was the predominant pathogen (85.7%). Microbiological clearance in follow-up cultures was observed in 85.7% of patients with available microbiological data, and clinical improvement was noted in most patients in this critically ill population. Infection-related mortality was 19% and was primarily associated with host-related factors, including younger age and immunosuppression. Resistance emergence during therapy was observed in one patient. Such resistance development during CZA treatment has been reported rarely in the literature and may involve mechanisms such as mutations in carbapenemase enzymes or alterations in bacterial permeability. In our study, resistance was detected during ongoing therapy in a single patient with Klebsiella pneumoniae , highlighting the importance of close microbiological monitoring in critically ill patients receiving prolonged treatment. Conclusion : CZA was used as a salvage treatment in critically ill children with MDR and PDR Gram-negative infections, with favorable clinical and microbiological outcomes observed. These real-world data support its cautious incorporation into pediatric antimicrobial stewardship strategies in PICU settings. What is Known: • Ceftazidime–avibactam is a promising agent against carbapenem-resistant Enterobacterales in adults. • Pediatric data remain limited, especially in critically ill children with MDR or PDR infections. What is New: • Ceftazidime–avibactam was used as salvage therapy for multidrug- and pandrug-resistant Gram-negative infections in critically ill children. • Clinical and microbiological response was achieved in a high-risk PICU population despite prolonged hospitalization and extensive prior antibiotic exposure.
2 October 2025 in Pediatric Transplantation